What are the criteria for adding ivabradine (Procoralan) in adult patients with coronary artery disease or chronic heart failure?

Criteria for Adding Ivabradine (Procoralan)

Ivabradine should be added as antianginal therapy in patients with chronic coronary syndrome who have left ventricular systolic dysfunction (LVEF <40%) and inadequate symptom control despite optimal medical therapy, or in heart failure patients with reduced ejection fraction (LVEF ≤35%) who remain symptomatic despite guideline-directed medical therapy including maximum tolerated beta-blocker doses, are in sinus rhythm, and have a resting heart rate ≥70 bpm. 1, 2

For Chronic Coronary Syndrome (CCS)

Primary Indication

• LVEF <40% with inadequate angina control despite beta-blockers and/or calcium channel blockers 1
• May be used as add-on therapy or as part of initial treatment in properly selected patients 1

Critical Exclusion

• Ivabradine is NOT recommended in CCS patients with LVEF >40% and no clinical heart failure 1
• This represents a Class III recommendation (harm) based on the SIGNIFY trial 3, which showed ivabradine did not improve outcomes and was associated with increased adverse events in patients with stable CAD without heart failure and LVEF >40%

Contraindications

• Non-dihydropyridine calcium channel blockers (verapamil, diltiazem) 1
• Strong CYP3A4 inhibitors 1
• Atrial fibrillation or other non-sinus rhythms 2

For Heart Failure with Reduced Ejection Fraction (HFrEF)

Specific Criteria (Class IIa Recommendation)

• LVEF ≤35% 2
• NYHA Class II-III symptoms despite guideline-directed medical therapy 2
• Sinus rhythm (mandatory) 2
• Resting heart rate ≥70 bpm 2
• On maximum tolerated dose of beta-blocker 2
• History of HF hospitalization within the preceding 12 months 2

Key Implementation Points

Beta-blocker optimization is mandatory first: Only 25% of patients in the SHIFT trial were on optimal beta-blocker doses, yet beta-blockers have proven mortality benefits that ivabradine does not replicate 2. Therefore, beta-blockers must be uptitrated to target doses as tolerated before considering ivabradine 2.

Primary benefit is hospitalization reduction: The SHIFT trial demonstrated an 18% relative risk reduction in the composite endpoint of cardiovascular death or HF hospitalization, with the greatest benefit being reduction in HF hospitalizations rather than mortality 2, 4.

Heart rate is the therapeutic target: The benefit of ivabradine results directly from heart rate reduction. In SHIFT, ivabradine reduced heart rate by approximately 6 bpm at 12 months compared to placebo 5.

Clinical Algorithm for Adding Ivabradine

Step 1: Determine Patient Category

• CCS with LVEF <40% → Consider for angina control
• HFrEF with LVEF ≤35% → Consider for symptom/hospitalization reduction
• CCS with LVEF >40% without HF → Do NOT use (contraindicated) 1

Step 2: Verify Prerequisites

• Confirm sinus rhythm (check ECG)
• Measure resting heart rate (must be ≥70 bpm)
• Document beta-blocker at maximum tolerated dose
• Ensure no concurrent non-DHP CCB or strong CYP3A4 inhibitors

Step 3: Dosing Strategy

• Start at 5 mg twice daily 2
• Target dose: 7.5 mg twice daily 2
• Adjust to achieve target heart rate of 55-60 bpm 3

Common Pitfalls to Avoid

Do not use ivabradine as a beta-blocker substitute: The mortality benefits of beta-blockers in HFrEF are well-established. Ivabradine is an add-on therapy, not a replacement 2.

Do not use in patients with LVEF >40% and stable CAD: The SIGNIFY trial specifically showed potential harm in this population, with no benefit on the primary composite endpoint and increased bradycardia (18.0% vs 2.3%) 3.

Monitor for bradycardia: This is the most common adverse event, occurring in approximately 18% of patients 3. Dose adjustment or discontinuation may be necessary.

Avoid in atrial fibrillation: Ivabradine works by inhibiting the If current in the sinoatrial node and is ineffective in atrial fibrillation 2.

Evidence Quality Considerations

The 2024 ESC Guidelines 1 provide the most current recommendations, downgrading ivabradine's role in CCS compared to previous guidelines and explicitly contraindicating its use in patients with preserved LVEF. The 2022 AHA/ACC/HFSA Guidelines 2 maintain a Class IIa recommendation for HFrEF based on the SHIFT trial, which remains the highest quality evidence for ivabradine's benefits in reducing HF hospitalizations.